Worldwide Opportunity Outlook on the Anti-obesity Drugs Market to 2022 - Key Players are Eisai, Novo Nordisk and Vivus - ResearchAndMarkets.com

December 6, 2018

DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Anti-obesity Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The anti-obesity drugs market is projected to register a CAGR of almost 8% by 2023.

The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic of obesity and type 2 diabetes is increasing. This demands increasing focus on the drugs that can control obesity and diabetes.

Global increase in both incidence and prevalence of obesity

The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.

Limited reimbursement for anti-obesity drugs

Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. Bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.

Market Trends

Research on Drugs that Target Both Obesity and Type 2 Diabetes Mellitus Increase in Childhood Obesity Incidence Use of Implantable Neuroregulatory Devices for Treating Obesity Increase in Morbid Obesity Incidence

Key Players

Eisai Novo Nordisk Vivus

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Market Sizing

6. Five Forces Analysis

7. Pipeline Analysis

8. Market Segmentation by Drugs Based on Class of Obesity

9. Market Segmentation by Mechanism of Action

10. Customer Landscape

11. Regional Landscape

12. Decision Framework

13. Drivers and Challenges

14. Market Trends

15. Vendor Landscape

16. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/k3n82x/worldwide?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005653/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Anti-Obesity Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/06/2018 11:21 AM/DISC: 12/06/2018 11:21 AM


Update hourly